Unique Wealth LLC raised its stake in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 303.7% during the 3rd quarter, Holdings Channel.com reports. The fund owned 1,401 shares of the company’s stock after acquiring an additional 1,054 shares during the period. Unique Wealth LLC’s holdings in Eli Lilly and Company were worth $1,241,000 as of its most recent SEC filing.
A number of other hedge funds have also recently bought and sold shares of LLY. Vanguard Group Inc. lifted its position in shares of Eli Lilly and Company by 1.6% during the first quarter. Vanguard Group Inc. now owns 72,745,011 shares of the company’s stock valued at $56,592,709,000 after purchasing an additional 1,133,810 shares in the last quarter. Capital Research Global Investors lifted its position in shares of Eli Lilly and Company by 6.0% during the 1st quarter. Capital Research Global Investors now owns 8,031,531 shares of the company’s stock worth $6,248,210,000 after buying an additional 453,939 shares in the last quarter. Capital International Investors boosted its stake in shares of Eli Lilly and Company by 5.1% in the 1st quarter. Capital International Investors now owns 6,972,393 shares of the company’s stock worth $5,424,243,000 after buying an additional 335,560 shares during the last quarter. Fisher Asset Management LLC boosted its stake in shares of Eli Lilly and Company by 1.9% in the 4th quarter. Fisher Asset Management LLC now owns 4,542,089 shares of the company’s stock worth $2,647,675,000 after buying an additional 85,015 shares during the last quarter. Finally, GQG Partners LLC grew its holdings in shares of Eli Lilly and Company by 20.2% in the first quarter. GQG Partners LLC now owns 3,848,886 shares of the company’s stock valued at $2,994,280,000 after acquiring an additional 648,094 shares in the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.
Insider Activity at Eli Lilly and Company
In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 210,000 shares of the stock in a transaction that occurred on Wednesday, July 10th. The shares were sold at an average price of $939.82, for a total value of $197,362,200.00. Following the sale, the insider now directly owns 96,943,810 shares in the company, valued at approximately $91,109,731,514.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.13% of the stock is owned by corporate insiders.
Wall Street Analyst Weigh In
Check Out Our Latest Stock Analysis on LLY
Eli Lilly and Company Price Performance
Shares of NYSE LLY opened at $885.15 on Friday. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11. Eli Lilly and Company has a fifty-two week low of $523.63 and a fifty-two week high of $972.53. The stock has a market cap of $841.25 billion, a PE ratio of 130.36, a price-to-earnings-growth ratio of 2.78 and a beta of 0.42. The stock has a fifty day moving average of $898.50 and a 200-day moving average of $846.49.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last posted its earnings results on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The business had revenue of $11.30 billion during the quarter, compared to analyst estimates of $9.83 billion. Equities research analysts anticipate that Eli Lilly and Company will post 16.49 earnings per share for the current year.
Eli Lilly and Company Company Profile
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Featured Articles
- Five stocks we like better than Eli Lilly and Company
- There Are Different Types of Stock To Invest In
- When Is the Best Time to Invest in Mutual Funds?
- Why Invest in 5G? How to Invest in 5G Stocks
- Is NVIDIA Stock in a Correction or Consolidation?
- Bank Stocks – Best Bank Stocks to Invest In
- 3 Oversold Stocks with Big RSI Rebound Potential
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.